Patel VG - Search Results

1

Treatment of muscle-invasive and advanced bladder cancer in 2020.

Patel VG, Oh WK, Galsky MD. Patel VG, et al. CA Cancer J Clin. 2020 Sep;70(5):404-423. doi: 10.3322/caac.21631. Epub 2020 Aug 7. CA Cancer J Clin. 2020. PMID: 32767764 Free article. Review.

2

Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.

Galsky MD, Hahn NM, Wong B, Lee KM, Argiriadi P, Albany C, Gimpel-Tetra K, Lowe N, Shahin M, Patel V, Tsao CK, Oh WK. Galsky MD, et al. Cancer Chemother Pharmacol. 2015 Dec;76(6):1259-65. doi: 10.1007/s00280-015-2884-7. Epub 2015 Oct 13. Cancer Chemother Pharmacol. 2015. PMID: 26464352 Clinical Trial.

3

Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition.

Collazo-Lorduy A, Castillo-Martin M, Wang L, Patel V, Iyer G, Jordan E, Al-Ahmadie H, Leonard I, Oh WK, Zhu J, McBride RB, Cordon-Cardo C, Solit DB, Sfakianos JP, Galsky MD. Collazo-Lorduy A, et al. Eur Urol. 2016 Nov;70(5):771-775. doi: 10.1016/j.eururo.2016.04.037. Epub 2016 May 10. Eur Urol. 2016. PMID: 27178450 Free PMC article.

4

Survival after Metastasectomy for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.

Patel V, Collazo Lorduy A, Stern A, Fahmy O, Pinotti R, Galsky MD, Gakis G. Patel V, et al. Bladder Cancer. 2017 Apr 27;3(2):121-132. doi: 10.3233/BLC-170108. Bladder Cancer. 2017. PMID: 28516157 Free PMC article.

5

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.

Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B, Gnjatic S, Schadt EE, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov AV. Galsky MD, et al. Among authors: patel vg. Eur Urol. 2018 May;73(5):751-759. doi: 10.1016/j.eururo.2017.12.001. Epub 2017 Dec 13. Eur Urol. 2018. PMID: 29248319 Clinical Trial.

6

The role of ketoconazole in current prostate cancer care.

Patel V, Liaw B, Oh W. Patel V, et al. Nat Rev Urol. 2018 Oct;15(10):643-651. doi: 10.1038/s41585-018-0077-y. Nat Rev Urol. 2018. PMID: 30154429 Review.

7

Atezolizumab in "Real World" Patients: Do Phase 3b Trials Help Bridge the Gap Between Efficacy and Effectiveness?

Patel VG, Galsky MD. Patel VG, et al. Eur Urol. 2019 Jul;76(1):82-83. doi: 10.1016/j.eururo.2019.04.004. Epub 2019 Apr 19. Eur Urol. 2019. PMID: 31006493 No abstract available.

8

The evolving landscape of immunotherapy in advanced prostate cancer.

Patel VG, Oh WK. Patel VG, et al. Immunotherapy. 2019 Jul;11(10):903-912. doi: 10.2217/imt-2019-0019. Epub 2019 Jun 4. Immunotherapy. 2019. PMID: 31161846

9

Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.

Niglio SA, Jia R, Ji J, Ruder S, Patel VG, Martini A, Sfakianos JP, Marqueen KE, Waingankar N, Mehrazin R, Wiklund P, Oh WK, Mazumdar M, Ferket BS, Galsky MD. Niglio SA, et al. Among authors: patel vg. Eur Urol. 2019 Dec;76(6):782-789. doi: 10.1016/j.eururo.2019.05.037. Epub 2019 Jun 11. Eur Urol. 2019. PMID: 31200951

10

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.

Davis AA, Patel VG. Davis AA, et al. Among authors: patel vg. J Immunother Cancer. 2019 Oct 26;7(1):278. doi: 10.1186/s40425-019-0768-9. J Immunother Cancer. 2019. PMID: 31655605 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

110 results

Search Page